カテゴリ： GlobalData, フランス, 企業調査

Ipsen SA (IPN)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Ipsen SA (IPN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9822
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：144
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：フランス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Ipsen SA (Ipsen) is a global specialty biopharmaceutical company that manufactures and distributes drugs for the treatment of cancer and rare and neurological diseases. The company develops and commercializes novel medicines in cancer, neuroscience and rare diseases. It also offers products to treat gastrointestinal disorders, neurodegenerative pathologies and rheumatology diseases. Ipsen sells its drugs through distributors and directly to hospitals in some countries. It has research and development (R&D) facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company provides products in Europe, North America, Asia and rest of the world. Ipsen is headquartered in Paris, France.

Ipsen SA (IPN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Ipsen SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Ipsen SA, Medical Devices Deals, 2012 to YTD 2018 13
Ipsen SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Ipsen SA, Pharmaceuticals & Healthcare, Deal Details 18
Asset Purchase 18
Ipsen Acquires Healthcare Portfolio from Sanofi for USD88.3 Million 18
Ipsen Acquires Oncology Assets from Merrimack Pharma 20
Venture Financing 22
Rhythm Pharma Raises USD41 Million in Mezzanine Financing 22
Rhythm Metabolic Raises USD40 Million in Series A Financing Round 24
Rhythm Pharma Raises US$33 Million In Series B Financing 26
Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 28
Rhythm Pharma Raises US$9.5 Million In Venture Financing 30
Partnerships 31
Arix Bioscience and Ipsen Enter into Co-Development Agreement 31
Ipsen Enters into Co-Promotion Agreement with Saol Therapeutics 32
Ipsen Enters into Research Agreement with Institute of Molecular and Cell Biology 33
Ipsen Partners with Oncodesign 34
Ipsen Enters into Research Agreement with PeptiMimesis 35
Ipsen Enters into Research Agreement with Aepodia 36
Galderma Enters into Distribution Agreement with Ipsen for Dysport in Asia-Pacific 37
Ipsen Enters into Research Agreement with Interprotein 38
Ipsen and EpiVax Enter into Partnership 39
Ipsen Enters into Research Agreement with Hannover Medical School 40
Ipsen and CNRS Enter into Agreement with CEA and University of Rennes 41
Ipsen Extends Research Agreement with Salk Institute for Biological Studies 42
Ipsen Extends Distribution Agreement with Galderma for Dysport 43
GW Pharma Enters Into Distribution Agreement With Ipsen For Sativex 45
Ipsen And Mayoly Spindler Enter Into Cross-Promotion Agreement For Primary Care Activities In France 46
Ipsen Enters Into Research Agreement With Harvard Medical School To Discover Botulinum Toxins 47
PeptiDream Expands Co-Development Agreement With Ipsen For Peptide Drugs 48
PeptiDream Enters Into Research Agreement With Ipsen To Discover Therapeutic Peptides 49
Oncodesign And Laboratory For Neurobiology and Gene Therapy Enter Into Research Agreement With Ipsen For Parkinson’s Disease 50
Ipsen Extends Distribution Agreement With Galderma For Dysport 52
Oncodesign Enters into Research Agreement with Ipsen 53
Licensing Agreements 54
Ipsen Enters into Licensing Agreement with MD Anderson 54
Merrimack Pharma Enters into Licensing Agreement with Ipsen 55
Ipsen Amends Licensing Agreement with Exelixis 56
Ipsen Enters into Licensing Agreement with 3B Pharma 57
Ipsen Enters into Licensing Agreement with Telesta Therapeutics 58
Lexicon Pharma Expands Licensing Agreement with Ipsen 59
Otonomy Enters into Licensing Agreement with Ipsen 60
Lexicon Pharma Expands Licensing Agreement with Ipsen for Telotristat Etiprate 61
Ipsen Enters into Licensing Agreement with Probi 63
Daewoong Enters Into Licensing Agreement With Ipsen Tianjin For Smecta Technology 64
Ipsen Enters Into Licensing Agreement With Inspiration Biopharma For IB1001 and OBI-1 65
Equity Offering 66
Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 66
Debt Offering 68
Ipsen Raises USD341 Million in Public Offering of 1.875% Notes Due 2023 68
Asset Transactions 69
Baxter International Completes Acquisition Of Rights To OBI- 1 And Related Assets From Ipsen And Inspiration Biopharma For USD700 Million 69
Cangene Completes Acquisition Of Rights To Hemophilia Products From Ipsen And Inspiration For US$300 Million 71
Acquisition 73
Ipsen to Acquire Equity Stake in Akkadeas Pharma 73
Ipsen Acquires Canbex Therapeutics 74
Ipsen Acquires OctreoPharm Sciences for USD57 Million 75
Ipsen Acquires Syntaxin, Life Sciences Company, For USD206 Million 76
Ipsen Sells 19.31% Stake In Spirogen, Developer Of DNA Sequence-Targeted Agents 78
Ipsen SA – Key Competitors 79
Ipsen SA – Key Employees 80
Ipsen SA – Locations And Subsidiaries 82
Head Office 82
Other Locations & Subsidiaries 82
Affiliate 84
Joint Venture 84
Recent Developments 85
Financial Announcements 85
Oct 25, 2018: Ipsen delivers strong sales growth of 20.2%1 for the third quarter of 2018 and confirms full year guidance 85
Jul 26, 2018: Ipsen delivers strong results for the first half of 2018 with sales growth of 21.5% and upgrades its guidance for full year 2018 87
Feb 15, 2018: Ipsen Delivers Strong 2017 Results with 21.1%1 Sales Growth and Core Operating Margin Increase of 3.4 Points and Expects Significant Further Growth in Sales and Margin in 2018 88
Jul 27, 2017: Ipsen Delivers Strong Sales Growth of 18.8% in the First Half of 2017 and Upgrades Its Guidance for Full Year 2017 90
Apr 27, 2017: Ipsen Reports Strong First Quarter 2017 Sales Growth of 19,1%1 98
Feb 23, 2017: Ipsen delivers strong 2016 results and expects further sales growth and margin enhancement for 2017 101
Corporate Communications 109
Sep 27, 2018: Ipsen names Dr. Yan Moore as Senior Vice President, Head of Oncology therapeutic area; and Dr. Alexander McEwan, FRCPC, as Vice President, Head of Radiopharmaceuticals 109
Mar 13, 2018: Ipsen Announces Executive Leadership Appointments 110
Jan 26, 2018: Dr Sotirios G. Stergiopoulos appointed as Ipsen Chief Medical Officer 111
Jan 12, 2018: Ipsen Appoints Richard Paulson Executive Vice-President and Chief Executive Officer of Ipsen North America 112
Apr 14, 2017: Ipsen appoints Dr. Alexandre Lebeaut as Executive Vice-President, R&D, and Chief Scientific Officer 113
Feb 06, 2017: Ipsen announces appointment of Dr. Sotirios G. Stergiopoulos as Head of Global Medical Affairs 114
Jan 20, 2017: Ipsen appoints Harout Semerjian as President, Head of Specialty Care International Region & Global Franchises 115
Product News 116
09/18/2017: U.S. FDA Approves New Indication for Ipsen’s Somatuline Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome 116
09/04/2017: Ipsen To Present Data on Somatuline at European Society of Medical Oncology congress 117
07/21/2017: Radius Health Announces that the CHMP Has Issued a Second Day-180 List of Outstanding Issues in its Regulatory Review of Eladynos (Abaloparatide-SC), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture 118
07/03/2017: Somatuline Autogel 120 mg receives Japanese approval for a new indication for the treatment of gastro-entero-pancreatic neuroendocrine tumors 119
06/01/2017: Ipsen To Present New Data of Lanreotide at ASCO 120
06/01/2017: Ipsen To Present New Data on Investigational Compound Lu-OPS201 at ASCO 121
05/01/2018: Novel Theranostic Approach for Treating Pancreatic Cancer Patients Shows Promise 122
04/17/2017: Merrimack Appoints Daryl Drummond, Ph.D. as Head of Research 123
03/09/2017: Ipsen announces data presentation on lanreotide (Somatuline Autogel) at the European Neuroendocrine Tumor Society (ENETS) 2017 conference 124
03/09/2017: Ipsen announces presentation on the investigational compound 177Lu-OPS201 at the European Neuroendocrine Tumor Society (ENETS) 2017 conference 126
02/13/2018: Health Canada approves Ipsen Somatuline Autogel for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs) 127
01/15/2018: Ipsen To Present Abstracts On lanreotide ASCO Gastrointestinal Symposium 2018 128
Product Approvals 129
Apr 28, 2017: FDA Approves Radius Healths TYMLOS (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture 129
Mar 28, 2017: NICE says pancreatic cancer drug is not cost effective for routine NHS use 131
Mar 13, 2017: Shire’s Onivyde Rejects For Use Within NHS Scotland 132
Mar 10, 2017: Radius Health Receives Notification of PDUFA Extension for Abaloparatide-SC 133
Clinical Trials 134
Jun 01, 2017: Ipsen Announces Presentation of New Data on Irinotecan at ASCO 134
May 24, 2017: Radius Announces Positive Top-Line Results from Completed ACTIVExtend Study for TYMLOS in Postmenopausal Women with Osteoporosis 135
Apr 03, 2017: New Analysis from ACTIVE Showed Consistent Fracture Reductions for Abaloparatide-SC Across Geographies 136
Mar 27, 2017: Merrimack to Present Data on MM-398 at the 2017 American Association for Cancer Research Annual Meeting 138
Feb 01, 2017: Mayo Clinic Proceedings Publishes Positive Results from the ACTIVExtend Clinical Trial of Abaloparatide-SC in Postmenopausal Women With Osteoporosis 139
Other Significant Developments 141
Oct 04, 2018: Ipsen Joins Biotechnology Innovation Organization (BIO) to advance growth and innovation 141
Jul 10, 2018: Ipsen welcomes Frederique Vidal, Minister of Higher Education, Research and Innovation, at its new development center in Dreux 142
Jun 07, 2018: Global Biopharmaceutical Company, Ipsen Announces New Headquarters for North America will be located in Cambridge, Massachusetts 143
Appendix 144
Methodology 144
About GlobalData 144
Contact Us 144
Disclaimer 144

List of Tables
Ipsen SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Ipsen SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Ipsen SA, Deals By Therapy Area, 2012 to YTD 2018 11
Ipsen SA, Medical Devices Deals, 2012 to YTD 2018 13
Ipsen SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Ipsen Acquires Healthcare Portfolio from Sanofi for USD88.3 Million 18
Ipsen Acquires Oncology Assets from Merrimack Pharma 20
Rhythm Pharma Raises USD41 Million in Mezzanine Financing 22
Rhythm Metabolic Raises USD40 Million in Series A Financing Round 24
Rhythm Pharma Raises US$33 Million In Series B Financing 26
Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 28
Rhythm Pharma Raises US$9.5 Million In Venture Financing 30
Arix Bioscience and Ipsen Enter into Co-Development Agreement 31
Ipsen Enters into Co-Promotion Agreement with Saol Therapeutics 32
Ipsen Enters into Research Agreement with Institute of Molecular and Cell Biology 33
Ipsen Partners with Oncodesign 34
Ipsen Enters into Research Agreement with PeptiMimesis 35
Ipsen Enters into Research Agreement with Aepodia 36
Galderma Enters into Distribution Agreement with Ipsen for Dysport in Asia-Pacific 37
Ipsen Enters into Research Agreement with Interprotein 38
Ipsen and EpiVax Enter into Partnership 39
Ipsen Enters into Research Agreement with Hannover Medical School 40
Ipsen and CNRS Enter into Agreement with CEA and University of Rennes 41
Ipsen Extends Research Agreement with Salk Institute for Biological Studies 42
Ipsen Extends Distribution Agreement with Galderma for Dysport 43
GW Pharma Enters Into Distribution Agreement With Ipsen For Sativex 45
Ipsen And Mayoly Spindler Enter Into Cross-Promotion Agreement For Primary Care Activities In France 46
Ipsen Enters Into Research Agreement With Harvard Medical School To Discover Botulinum Toxins 47
PeptiDream Expands Co-Development Agreement With Ipsen For Peptide Drugs 48
PeptiDream Enters Into Research Agreement With Ipsen To Discover Therapeutic Peptides 49
Oncodesign And Laboratory For Neurobiology and Gene Therapy Enter Into Research Agreement With Ipsen For Parkinson's Disease 50
Ipsen Extends Distribution Agreement With Galderma For Dysport 52
Oncodesign Enters into Research Agreement with Ipsen 53
Ipsen Enters into Licensing Agreement with MD Anderson 54
Merrimack Pharma Enters into Licensing Agreement with Ipsen 55
Ipsen Amends Licensing Agreement with Exelixis 56
Ipsen Enters into Licensing Agreement with 3B Pharma 57
Ipsen Enters into Licensing Agreement with Telesta Therapeutics 58
Lexicon Pharma Expands Licensing Agreement with Ipsen 59
Otonomy Enters into Licensing Agreement with Ipsen 60
Lexicon Pharma Expands Licensing Agreement with Ipsen for Telotristat Etiprate 61
Ipsen Enters into Licensing Agreement with Probi 63
Daewoong Enters Into Licensing Agreement With Ipsen Tianjin For Smecta Technology 64
Ipsen Enters Into Licensing Agreement With Inspiration Biopharma For IB1001 and OBI-1 65
Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 66
Ipsen Raises USD341 Million in Public Offering of 1.875% Notes Due 2023 68
Baxter International Completes Acquisition Of Rights To OBI- 1 And Related Assets From Ipsen And Inspiration Biopharma For USD700 Million 69
Cangene Completes Acquisition Of Rights To Hemophilia Products From Ipsen And Inspiration For US$300 Million 71
Ipsen to Acquire Equity Stake in Akkadeas Pharma 73
Ipsen Acquires Canbex Therapeutics 74
Ipsen Acquires OctreoPharm Sciences for USD57 Million 75
Ipsen Acquires Syntaxin, Life Sciences Company, For USD206 Million 76
Ipsen Sells 19.31% Stake In Spirogen, Developer Of DNA Sequence-Targeted Agents 78
Ipsen SA, Key Competitors 79
Ipsen SA, Key Employees 80
Ipsen SA, Subsidiaries 82
Ipsen SA, Affiliate 84
Ipsen SA, Joint Venture 84

List of Figures
Ipsen SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Ipsen SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Ipsen SA, Medical Devices Deals, 2012 to YTD 2018 13

★海外企業調査レポート[Ipsen SA (IPN)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Exonate Ltd-製薬・医療分野：企業M&A・提携分析
    Summary Exonate Ltd (Exonate) is a biopharmaceutical company that discovers and develops small molecule drugs which modulates the alternative mRNA splicing for the treatment of unmet medical needs. The comany's alternative mRNA splicing is modulated in disease states that results in the pathological …
  • Tampa Electric Co：企業の発電所・SWOT分析2018
    Tampa Electric Co - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees ( …
  • Top Image Systems Ltd (TISA)：企業の戦略的SWOT分析
    Top Image Systems Ltd (TISA) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • PowerVision Inc：医療機器：M&Aディール及び事業提携情報
    Summary PowerVision Inc (PowerVision) is a medical device company which focused on developing fluid-based accommodating intraocular lenses (AIOL) for presbyopia and cataracts patients. The company offers FluidVision accommodating intraocular lens technology which provides true accommodation by imita …
  • Option Care Health Inc (OPCH)：企業の財務・戦略的SWOT分析
    Option Care Health Inc (OPCH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Rum Group for Transportation & Tourism Investment：企業の戦略・SWOT・財務情報
    Rum Group for Transportation & Tourism Investment - Strategy, SWOT and Corporate Finance Report Summary Rum Group for Transportation & Tourism Investment - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structur …
  • Sparton Resources Inc (SRI)：企業の財務・戦略的SWOT分析
    Summary Sparton Resources Inc (Sparton Resources) is a diversified company that acquires and develops oil and gas properties in North America and China. The company’s products include vanadium, natural gas, crude oil, gold, and vanadium flow batteries, among others. Its energy projects comprise Sier …
  • PUMA SE：企業の戦略・SWOT・財務情報
    PUMA SE - Strategy, SWOT and Corporate Finance Report Summary PUMA SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Deutsche Bank AG (DBK)：企業の財務・戦略的SWOT分析
    Deutsche Bank AG (DBK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • PerkinElmer, Inc.：企業の戦略・SWOT・財務情報
    PerkinElmer, Inc. - Strategy, SWOT and Corporate Finance Report Summary PerkinElmer, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Glanbia Nutritionals Inc：企業の戦略的SWOT分析
    Glanbia Nutritionals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • GrafTech International Ltd：企業の戦略・SWOT・財務情報
    GrafTech International Ltd - Strategy, SWOT and Corporate Finance Report Summary GrafTech International Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Terex Corp
    Terex Corp - Strategy, SWOT and Corporate Finance Report Summary Terex Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Mitsubishi Ufj Financial Group Inc：企業の戦略・SWOT・財務分析
    Mitsubishi Ufj Financial Group Inc - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Ufj Financial Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • iVascular SLU：企業の製品パイプライン分析2018
    Summary iVascular SLU (iVascular) is a designer and developer of advanced medical devices and implants for the treatment of cardiovascular system disorders. The company offers products in the fields of interventional cardiology, endovascular intervention and interventional neuroradiology including d …
  • Jubilee Life Insurance Company Limited：企業の戦略・SWOT・財務情報
    Jubilee Life Insurance Company Limited - Strategy, SWOT and Corporate Finance Report Summary Jubilee Life Insurance Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Alimentation Couche-Tard Inc. (ATD.B)-石油・ガス分野：企業M&A・提携分析
    Summary Alimentation Couche-Tard Inc. (Couche-Tard) is a retail company that operates an extensive network of convenience stores. The company principally offers food and non-food items as well as transportation fuels. Couche-Tard products include tobacco, alcohol, grocery items, candy, snacks and va …
  • El Pollo Loco Holdings, Inc.：企業の戦略・SWOT・財務情報
    El Pollo Loco Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary El Pollo Loco Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • AltaGas Ltd (ALA)：企業の財務・戦略的SWOT分析
    AltaGas Ltd (ALA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Volta River Authority-エネルギー分野：企業M&A・提携分析
    Summary Volta River Authority (VRA) is a state-owned energy utility that generates, transmits, and distributes electricity. The authority produces power from solar, hydro, light crude oil, distillate fuel oil, and heavy fuel oil sources. It procures energy from Takoradi International Company Ltd; an …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆